Skip to main content
NVCR
NASDAQ Industrial Applications And Services

NovoCure Beats on Q3 Revenue, Raises 2026 Guidance and Adjusted EBITDA Outlook

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$14.25
Mkt Cap
$1.65B
52W Low
$9.82
52W High
$21.451
52W Position info
45% above low
Off High info
34% below high
Rel. Volume info
1.8× avg
Market data snapshot near publication time

NVCR sits 45% above its 52-week low of $9.82.

Summary

NovoCure reported Q3 2026 revenue of $193.4M, up 16%, with adjusted EBITDA of $15.7M, and raised full-year revenue and adjusted EBITDA guidance.


Key Events · Earnings and Guidance · NVCR

  • Q3 Revenue Up 16% to $193.4M

    Net revenues rose to $193.4M from $167.2M a year earlier, driven by 19% growth in global active patients to 5,260.

  • Adjusted EBITDA Turns to $15.7M

    Adjusted EBITDA was $15.7M versus $(3.0)M in Q3 2025, and net loss narrowed to $10.4M ($0.09 per share) from $37.3M ($0.33).

  • 2026 Guidance Raised

    Full-year revenue guidance lifted to $736M-$743M from $710M-$725M; adjusted EBITDA guidance lifted to $24M-$34M from $0M-$15M.

  • Balance Sheet and Debt

    Cash, cash equivalents and short-term investments totaled $463.5M at September 30, 2026, against a $25.0M current maturity of the senior secured credit facility.


Analysis · NVCR · Industrial Applications And Services

NovoCure delivered $193.4M of Q3 revenue (up 16%) and swung to $15.7M of adjusted EBITDA from a small loss a year ago, then raised full-year revenue guidance to $736M-$743M and adjusted EBITDA to $24M-$34M. The EBITDA raise is the bigger change: the low end moved from $0 to $24M, which puts the company's path to profitability on a firmer footing. Cash of $463.5M against a $25M current debt maturity keeps the balance sheet comfortable, so this is an operating story rather than a financing one. The next hard datapoint is the FDA decision on brain metastases from NSCLC in Q4 2026.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NVCR was trading at $14.25 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $9.82 to $21.45. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NVCR - Latest Insights

NVCR
Nov 09, 2026, 6:59 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $13.95
Real-time Price: $11.49 info
Change: -$2.46 (-18%) info
Market Cap: $1.343B info
NVCR
Oct 29, 2026, 7:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $15.34
Real-time Price: $11.49 info
Change: -$3.85 (-25%) info
Market Cap: $1.343B info
NVCR
Oct 29, 2026, 6:59 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $14.25
Real-time Price: $11.49 info
Change: -$2.76 (-19%) info
Market Cap: $1.343B info
NVCR
Oct 01, 2026, 9:00 AM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $16.06
Real-time Price: $11.49 info
Change: -$4.57 (-28%) info
Market Cap: $1.343B info
NVCR
Sep 01, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $17.70
Real-time Price: $11.49 info
Change: -$6.21 (-35%) info
Market Cap: $1.343B info